Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants

Bruschettini, Matteo; Romantsik, Olga; Moreira, Alvaro; Ley, David; Thébaud, Bernard

doi:10.1002/14651858.cd013202.pub2

Cited by 17 publications

(7 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighty percent of these studies reported a significant improvement of cognitive and/or sensorimotor function, as well as decreased brain damage. There are no completed clinical trials on stem cell therapy, and several are ongoing [112]. Xenon [113] and magnesium sulphate [114] have been previously evaluated and did not demonstrate much benefit.…”

Section: Discussionmentioning

confidence: 99%

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

et al. 2021

View full text Add to dashboard Cite

Around 0.75 million babies worldwide suffer from moderate or severe hypoxic-ischemic encephalopathy (HIE) each year resulting in around 400,000 babies with neurodevelopmental impairment. In 2010, neonatal HIE was associated with 2.4% of the total Global Burden of Disease. Therapeutic hypothermia (TH), a treatment that is now standard of care in high-income countries, provides proof of concept that strategies that aim to improve neurodevelopment are not only possible but can also be implemented to clinical practice. While TH is beneficial, neonates with moderate or severe HIE treated with TH still experience devastating complications: 48% (range: 44–53) combined death or moderate/severe disability. There is a concern that TH may not be effective in low- and middle-income countries. Therapies that further improve outcomes are desperately needed, and in high-income countries, they must be tested in conjunction with TH. We have in this review focussed on pharmacological treatment options (e.g. erythropoietin, allopurinol, melatonin, cannabidiol, exendin-4/exenatide). Erythropoietin and allopurinol show promise and are progressing towards the clinic with ongoing definitive phase 3 randomised placebo-controlled trials. However, there remain global challenges for the next decade. Conclusion: There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials to avoid exposure to harmful medications or abandoning putative treatments. What is Known:• Therapeutic hypothermia is beneficial in neonatal hypoxic-ischemic encephalopathy.• Neonates with moderate or severe hypoxic-ischemic encephalopathy treated with therapeutic hypothermia still experience severe sequelae. What is New:• Erythropoietin, allopurinol, melatonin, cannabidiol, and exendin-4/exenatide show promise in conjunction with therapeutic hypothermia.• There is a need for more optimal animal models, greater industry support/sponsorship, increased use of juvenile toxicology, dose-ranging studies with pharmacokinetic-pharmacodynamic modelling, and well-designed clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the past few years, the effect of stem/progenitor cell transplantation has also been evaluated in animal models of HIE and the therapeutic potential to protect and regenerate in damaged brain has been clinically exemplified. Therapeutic potential has been exhibited in varieties of stem cells for HIE, including NSCs (Shimada et al, 2012) and OPCs (Bruschettini et al, 2020), MSCs (Bruschettini et al, 2020), ESCs (Peng et al, 2019), UMSCs (Lin et al, 2011), iPSCs (Ling et al, 2019), HSCs (Courties et al, 2015) and UCBCs (Figure 4). To achieve tissue repair and regeneration, stem cells are usually transplanted exogenously into the body or recruited endogenously within the body by available therapeutic options.…”

Section: Stem Cell‐based Therapy For Hiementioning

confidence: 99%

“…Transplantation of stem cells may level up brain trophic and antiapoptotic factors, ameliorate inflammatory response to protect endogenous tissue and promote replacement of damaged cells (Bennet et al, 2012). Therapeutic potency in neuroprotection or regeneration of the damaged brain for HIE has been exhibited in multifarious stem cells, including neural stem cells (NSCs) (Shimada et al, 2012) and oligodendrocyte progenitor cells (OPCs) (Bruschettini et al, 2020), mesenchymal stem cells (MSCs) (Bruschettini et al, 2020), embryonic stem cells (ESCs) (Peng et al, 2019), umbilical mesenchymal stem cells (UMSCs) (Lin et al, 2011), induced pluripotent stem cells (iPSCs) (Bruschettini et al, 2020), hematopoietic stem cells (HSCs) (Courties et al, 2015) and umbilical cord blood cells (UCBCs). Stem cell transplantation has verified its effectiveness and safety, so it may be used in the treatment of HIE.…”

Section: Introductionmentioning

confidence: 99%

The fate and prospects of stem cell therapy in the treatment of hypoxic–ischemic encephalopathy

Luo,

Zhou,

Sun

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

Hypoxic-ischemic encephalopathy (HIE) is a leading cause of long-term neurological disability in neonates and adults. Despite emerging advances in supportive care, like the most effective approach, hypothermia, poor prognosis has still been present in current clinical treatment for HIE. Stem cell therapy has been adopted for treating cerebral ischemia in preclinical and clinical trials, displaying its promising therapeutic value. At present, reported treatments for stroke employed stem cells to replace the lost neurons and integrate them into the existing host circuitry, promoting the release of growth factors to support and stimulate endogenous repair processes and so on. In this review, a meaningful overview to numerous studies published up to now was presented by introducing the preclinical and clinical research status of stem cell therapy for cerebral ischemia and hypoxia, discussing potential therapeutic mechanisms of stem cell transplantation for curing HI-induced brain injury, summarizing a series of approaches for marking transplanted cells and existing imaging systems for stem cell labelling and in vivo tracking and expounding the endogenous regeneration capability of stem cells in the newborn brain when subjected to an HI insult. Additionally, it is promising to combine stem therapy with neuromodulation through specific regulation of neural circuits.The crucial neural circuits across different brain areas related to functional recovery are of great significance for the application of neuromodulation strategies after the occurrence of neonatal hypoxic-ischemic encephalopathy (NHIE).

show abstract

“…Of note, concurrent with progressive developments in the field of stem cell therapy (SCT) is the monumental developments in the field of human medical imaging. The inception of echocardiography-computed tomography and magnet resonance imaging has revolutionized the diagnosis and follow-up strategies of a myriad of somatic and systemic lesions [ 30 ]. Towards the end of the previous century, the isolation of embryonic pluripotent stem cells brought much anticipation and excitement to the SCT field.…”

Section: Theory Of Stem Cell Therapy (Sct)mentioning

confidence: 99%

Stem Cell Therapy for Diabetic Foot Ulcers: Theory and Practice

Nalisa

Moneruzzaman

Changwe³

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

Diabetic foot ulcers are associated with increases in limb amputation, morbidity, and mortality. Recently, a stem cell application is emerging as promising adjuvant therapy. We presented available remedies by conducting a literature review on the application, safety, and efficacy of stem cell therapy. Relevant literature, including randomized control trials and article journals, was obtained from reputable search engines (PubMed, Scopus, and Web of Science). We analyzed five credible cohorts, with variable sources of stem cells, in a total of 216 participants, 151 males and 65 females, age ( mean ± SD ) of 64.5 ± 9.6 years. With an average success of 86.41% in all Wagner-II lesions, mesenchymal SCA (stem cell application) is safe and effective, hence can significantly prevent limb amputation.

show abstract

Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants

Cited by 17 publications

References 128 publications

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

New possibilities for neuroprotection in neonatal hypoxic-ischemic encephalopathy

The fate and prospects of stem cell therapy in the treatment of hypoxic–ischemic encephalopathy

Stem Cell Therapy for Diabetic Foot Ulcers: Theory and Practice

Contact Info

Product

Resources

About